Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Xenetic Biosciences Retained Earnings (Accumulated Deficit) 2013-2024 | XBIO

Xenetic Biosciences retained earnings (accumulated deficit) from 2013 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
  
Xenetic Biosciences Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $-193
2022 $-189
2021 $-183
2020 $-177
2019 $-166
2018 $-153
2017 $-146
2016 $-142
2015 $-88
2014 $-76
2013 $-58
2012 $-50
2011 $-50
Xenetic Biosciences Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-06-30 $-196
2024-03-31 $-194
2023-12-31 $-193
2023-09-30 $-192
2023-06-30 $-191
2023-03-31 $-190
2022-12-31 $-189
2022-09-30 $-188
2022-06-30 $-187
2022-03-31 $-184
2021-12-31 $-183
2021-09-30 $-181
2021-06-30 $-179
2021-03-31 $-178
2020-12-31 $-177
2020-09-30 $-176
2020-06-30 $-168
2020-03-31 $-167
2019-12-31 $-166
2019-09-30 $-165
2019-06-30 $-156
2019-03-31 $-155
2018-12-31 $-153
2018-09-30 $-152
2018-06-30 $-150
2018-03-31 $-148
2017-12-31 $-146
2017-09-30 $-150
2017-06-30 $-148
2017-03-31 $-145
2016-12-31 $-142
2016-09-30 $-142
2016-06-30 $-139
2016-03-31 $-92
2015-12-31 $-88
2015-09-30 $-85
2015-06-30 $-79
2015-03-31 $-78
2014-12-31 $-76
2014-09-30 $-71
2014-06-30 $-68
2014-03-31 $-65
2013-12-31 $-58
2013-09-30
2013-06-30
2013-03-31
2012-12-31 $-50
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.006B $0.003B
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $88.667B 35.33
Takeda Pharmaceutical (TAK) Japan $47.251B 9.46
Merck (MKGAF) Germany $23.748B 25.92
Astellas Pharma (ALPMY) Japan $21.535B 25.87
Summit Therapeutics (SMMT) United States $18.997B 0.00
Sandoz Group AG (SDZNY) Switzerland $17.531B 0.00
United Therapeutics (UTHR) United States $15.350B 15.86
Shionogi (SGIOY) Japan $13.285B 12.73
Neurocrine Biosciences (NBIX) United States $12.350B 36.95
Catalent (CTLT) United States $10.951B 0.00
Orion OYJ (ORINY) Finland $7.373B 30.02
Revolution Medicines (RVMD) United States $7.311B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.889B 7.31
Ionis Pharmaceuticals (IONS) United States $6.069B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.660B 0.00
Madrigal Pharmaceuticals (MDGL) United States $5.067B 0.00
Crinetics Pharmaceuticals (CRNX) United States $4.241B 0.00
Corcept Therapeutics (CORT) United States $4.149B 35.14
Dyne Therapeutics (DYN) United States $3.474B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.733B 15.77
PTC Therapeutics (PTCT) United States $2.698B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.488B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.426B 19.28
Soleno Therapeutics (SLNO) United States $2.057B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.900B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.845B 0.00
Xencor (XNCR) United States $1.640B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.639B 0.00
Harrow (HROW) United States $1.546B 0.00
Cassava Sciences (SAVA) United States $1.502B 0.00
Ardelyx (ARDX) United States $1.448B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.391B 0.00
Ocular Therapeutix (OCUL) United States $1.366B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.331B 0.00
Indivior (INDV) United States $1.311B 6.02
Evotec AG (EVO) Germany $1.290B 0.00
ARS Pharmaceuticals (SPRY) United States $1.265B 0.00
Collegium Pharmaceutical (COLL) United States $1.204B 6.91
Calliditas Therapeutics AB (CALT) Sweden $1.199B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.021B 0.00
Relay Therapeutics (RLAY) United States $1.018B 0.00
Enliven Therapeutics (ELVN) United States $1.014B 0.00
Bioventus (BVS) United States $0.921B 29.92
Cronos Group (CRON) Canada $0.864B 0.00
4D Molecular Therapeutics (FDMT) United States $0.840B 0.00
USANA Health Sciences (USNA) United States $0.761B 13.97
Savara (SVRA) United States $0.729B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.716B 44.80
ProKidney (PROK) United States $0.692B 0.00
Pacira BioSciences (PCRX) United States $0.662B 6.26
Corbus Pharmaceuticals Holdings (CRBP) United States $0.613B 0.00
Exscientia (EXAI) United Kingdom $0.608B 0.00
Siga Technologies (SIGA) United States $0.562B 6.74
Silence Therapeutics (SLN) United Kingdom $0.546B 0.00
Foghorn Therapeutics (FHTX) United States $0.544B 0.00
OmniAb (OABI) United States $0.541B 0.00
Altimmune (ALT) United States $0.538B 0.00
Eliem Therapeutics (ELYM) United States $0.534B 0.00
Tourmaline Bio (TRML) United States $0.496B 0.00
Sage Therapeutics (SAGE) United States $0.459B 0.00
KalVista Pharmaceuticals (KALV) United States $0.457B 0.00
Verve Therapeutics (VERV) United States $0.456B 0.00
Aquestive Therapeutics (AQST) United States $0.436B 0.00
Larimar Therapeutics (LRMR) United States $0.435B 0.00
Xeris Biopharma Holdings (XERS) United States $0.432B 0.00
Elite Pharmaceuticals (ELTP) United States $0.409B 38.25
Theravance Biopharma (TBPH) Cayman Islands $0.403B 0.00
Zevra Therapeutics (ZVRA) United States $0.396B 0.00
Organogenesis (ORGO) United States $0.386B 0.00
Lyell Immunopharma (LYEL) United States $0.356B 0.00
Esperion Therapeutics (ESPR) United States $0.349B 0.00
Korro Bio (KRRO) United States $0.347B 0.00
Aldeyra Therapeutics (ALDX) United States $0.343B 0.00
Lexeo Therapeutics (LXEO) United States $0.316B 0.00
ESSA Pharma (EPIX) Canada $0.300B 0.00
Heron Therapeutics (HRTX) United States $0.288B 0.00
Akebia Therapeutics (AKBA) United States $0.288B 0.00
Black Diamond Therapeutics (BDTX) United States $0.273B 0.00
Avita Medical (RCEL) United States $0.267B 0.00
Nature's Sunshine Products (NATR) United States $0.254B 17.35
Enanta Pharmaceuticals (ENTA) United States $0.247B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.241B 0.00
Nektar Therapeutics (NKTR) United States $0.239B 0.00
Nanobiotix S.A (NBTX) France $0.236B 0.00
Acrivon Therapeutics (ACRV) United States $0.235B 0.00
Pyxis Oncology (PYXS) United States $0.213B 0.00
CytoDyn (CYDY) United States $0.205B 0.00
MediWound (MDWD) Israel $0.200B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.199B 0.00
Profound Medical (PROF) Canada $0.188B 0.00
Innate Pharma SA (IPHYF) France $0.184B 0.00
Galectin Therapeutics (GALT) United States $0.173B 0.00
Telomir Pharmaceuticals (TELO) United States $0.166B 0.00
VAXART, INC (VXRT) United States $0.164B 0.00
Context Therapeutics (CNTX) United States $0.156B 0.00
Achieve Life Sciences (ACHV) Canada $0.154B 0.00
Cardiol Therapeutics (CRDL) Canada $0.150B 0.00
Century Therapeutics (IPSC) United States $0.141B 0.00
Prelude Therapeutics (PRLD) United States $0.135B 0.00
OptiNose (OPTN) United States $0.130B 0.00
Fractyl Health (GUTS) United States $0.128B 0.00
Assertio Holdings (ASRT) United States $0.124B 21.67
Incannex Healthcare (IXHL) Australia $0.118B 0.00
CASI Pharmaceuticals (CASI) China $0.107B 0.00
Regulus Therapeutics (RGLS) United States $0.105B 0.00
Journey Medical (DERM) United States $0.105B 0.00
Relmada Therapeutics (RLMD) United States $0.104B 0.00
Metagenomi (MGX) United States $0.103B 0.00
Karyopharm Therapeutics (KPTI) United States $0.094B 0.00
Citius Pharmaceuticals (CTXR) United States $0.091B 0.00
AlloVir (ALVR) United States $0.087B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.085B 0.00
Aclaris Therapeutics (ACRS) United States $0.083B 0.00
Arch Biopartners (ACHFF) Canada $0.078B 0.00
PMV Pharmaceuticals (PMVP) United States $0.077B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 368.33
Verrica Pharmaceuticals (VRCA) United States $0.076B 0.00
Vivani Medical (VANI) United States $0.069B 0.00
Champions Oncology (CSBR) United States $0.063B 0.00
Nutriband (NTRB) United States $0.062B 0.00
SCYNEXIS (SCYX) United States $0.060B 0.00
Mural Oncology (MURA) Ireland $0.057B 0.00
ProPhase Labs (PRPH) United States $0.050B 0.00
BioLineRx (BLRX) Israel $0.050B 0.00
Reneo Pharmaceuticals (RPHM) United States $0.046B 0.00
Inotiv (NOTV) United States $0.046B 0.00
FibroGen (FGEN) United States $0.045B 0.00
DURECT (DRRX) United States $0.044B 0.00
Carisma Therapeutics (CARM) United States $0.042B 0.00
Natural Alternatives (NAII) United States $0.040B 0.00
Rafael Holdings (RFL) United States $0.039B 0.00
ElectroCore (ECOR) United States $0.039B 0.00
Gain Therapeutics (GANX) United States $0.038B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.038B 0.00
Tempest Therapeutics (TPST) United States $0.038B 0.00
Protara Therapeutics (TARA) United States $0.038B 0.00
Unicycive Therapeutics (UNCY) United States $0.036B 0.00
Enlivex Therapeutics (ENLV) Israel $0.032B 0.00
Oruka Therapeutics (ORKA) United States $0.032B 0.00
VYNE Therapeutics (VYNE) United States $0.027B 0.00
Surrozen (SRZN) United States $0.026B 0.00
Lipocine (LPCN) United States $0.026B 0.00
Iterum Therapeutics (ITRM) Ireland $0.025B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.025B 0.00
Minerva Neurosciences (NERV) United States $0.020B 0.00
Cosmos Health (COSM) United States $0.020B 0.00
MEI Pharma (MEIP) United States $0.020B 0.77
TherapeuticsMD (TXMD) United States $0.020B 0.00
Lyra Therapeutics (LYRA) United States $0.018B 0.00
BioVie (BIVI) United States $0.018B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.018B 0.00
NRx Pharmaceuticals (NRXP) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
Indaptus Therapeutics (INDP) United States $0.015B 0.00
Talphera (TLPH) United States $0.015B 0.00
Aptorum Group (APM) United Kingdom $0.015B 0.00
Nuvilex (PMCB) United States $0.014B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Conduit Pharmaceuticals (CDT) United States $0.013B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.013B 0.00
Redhill Biopharma (RDHL) Israel $0.013B 0.00
Dominari Holdings (DOMH) United States $0.012B 0.00
Jaguar Animal Health (JAGX) United States $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.011B 0.00
GlycoMimetics (GLYC) United States $0.011B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Avalo Therapeutics (AVTX) United States $0.010B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.010B 0.00
Vivos Therapeutics (VVOS) United States $0.010B 0.00
Plus Therapeutics (PSTV) United States $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Viracta Therapeutics (VIRX) United States $0.009B 0.00
Inhibikase Therapeutics (IKT) United States $0.009B 0.00
Molecular Templates (MTEM) United States $0.009B 0.00
Mangoceuticals (MGRX) United States $0.007B 0.00
Biomerica (BMRA) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Heatwurx (PCSA) United States $0.005B 0.00
Oncternal Therapeutics (ONCT) United States $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.11
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Ainos (AIMD) United States $0.004B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.004B 0.00
SHINECO (SISI) China $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Bio-Path Holdings (BPTH) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
InMed Pharmaceuticals (INM) Canada $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
Aditxt (ADTX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
China SXT Pharmaceuticals (SXTC) China $0.000B 0.00
Qilian Holding Group (BGM) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 3.58
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 35.30